VISICORT
Adverse Immune Signatures and their Prevention in Corneal Transplantation
| Coordinatore | NATIONAL UNIVERSITY OF IRELAND, GALWAY
Organization address
address: University Road - contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 7˙789˙309 € |
| EC contributo | 5˙989˙491 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-04-01 - 2019-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
NATIONAL UNIVERSITY OF IRELAND, GALWAY
Organization address
address: University Road - contact info |
IE (GALWAY) | coordinator | 785˙110.00 |
| 2 |
Fios Genomics Limited
Organization address
address: Buchanan Street 166 contact info |
UK (Glasgow) | participant | 736˙604.70 |
| 3 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 714˙889.60 |
| 4 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 691˙000.00 |
| 5 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 653˙759.25 |
| 6 |
BIOSTOR IRELAND LIMITED
Organization address
address: KILRANE BUSINESS PARK contact info |
IE (ROSSLARE HARBOUR) | participant | 512˙261.20 |
| 7 |
ORBSEN THERAPEUTICS LIMITED
Organization address
address: ORBSEN BUILDING NATIONAL UNIVERSITY OF IRELAND contact info |
IE (GALWAY) | participant | 451˙320.00 |
| 8 |
AARHUS UNIVERSITETSHOSPITAL
Organization address
address: NORREBROGADE 44 contact info |
DK (AARHUS) | participant | 443˙582.40 |
| 9 |
ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
IE (DUBLIN) | participant | 394˙582.00 |
| 10 |
UNIVERSITY OF BRISTOL
Organization address
address: TYNDALL AVENUE SENATE HOUSE contact info |
UK (BRISTOL) | participant | 394˙582.00 |
| 11 |
PINTAIL LTD
Organization address
address: SPRINGHILL AVENUE 77 contact info |
IE (BLACKROCK) | participant | 195˙000.00 |
| 12 |
AARHUS UNIVERSITET
Organization address
address: Nordre Ringgade 1 contact info |
DK (AARHUS C) | participant | 16˙800.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- and partial-thickness procedures performed annually. Adverse immune responses occur in up to 30% of CT recipients causing rejection and failure. The high levels of CT clinical activity and immune complications create an ideal opportunity to comprehensively profile immune responses associated with adverse tissue transplant outcomes and to develop new approaches for their prevention or early diagnosis. VISICORT is a multi-disciplinary project with expertise in basic immunology, bio-sampling, systems biology/immune profiling, bioinformatics, clinical tissue transplantation and cell therapy. It will complete the first systematic immune profiling of biological samples from animal and human CT recipients with diverse outcomes. Clinical data and bio-specimens from over 700 CT recipients at 5 leading transplant centres will be centrally collated and distributed to cutting-edge university- and SME-based laboratories for multi-platform profiling and integrated bioinformatics analyses. Profiling data will generate better understanding of adverse immune reactions to tissue transplants. This knowledge will be used to develop novel biomarker-based surveillance strategies and, coupled with SME-based expertise in cell product development, will also inform the design and initiation of an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human CT recipients. VISICORT research will strongly impact multiple EU research/scientific communities, patient cohorts and SMEs and will have high commercialisation value for the biopharmaceutical and biotechnology industries.'